CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML

Lucas, Claire M., Scott, Laura J., Carmell, Natasha, Holcroft, Alison K., Hills, Robert K., Burnett, Alan K. and Clark, Richard E. 2018. CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances 2 (9) , p. 964. 10.1182/bloodadvances.2017013615

Preview

PDF - Published Version Download (812kB) | Preview

Abstract

PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Publisher:	American Society of Hematology: Blood Advances
ISSN:	2473-9529
Date of First Compliant Deposit:	3 August 2018
Date of Acceptance:	16 March 2018
Last Modified:	28 Apr 2020 12:29
URI:	http://orca.cf.ac.uk/id/eprint/113883

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item